Predictive IHC Markers in Breast Cancer 2020: What Have We Learned?

Recorded On: 10/15/2020

Back to Package

  • Register
    • Non-member - $30
    • Core Member - $25
    • Student Member - $25
    • Enhanced Member - $25

This workshop will review the current state of immunohistochemical testing for estrogen receptor protein, progesterone receptor protein, and HER2 protein overexpression in breast cancer.  Invasive, metastatic, and in situ cancer will be covered.  The importance of pre-analytics and technical issues in IHC testing will be addressed.  Proficiency testing and results from Oncotype DX™ testing will be used to discuss standardization and test validation.

CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of purchase. 

Richard Cartun, MS, PhD

Director, Histology/Morphologic Proteomics

Hartford Hospital

I currently serve as the Director of Histology, Immunopathology, and the Martin M. Berman, MD Morphologic Proteomics Laboratory at Hartford Hospital, a large tertiary care hospital in Hartford, CT.  I have been doing immunohistochemical testing for more than 40 years now and, as a result, have extensive knowledge in the technical aspects and interpretation of this valuable laboratory test.


Predictive IHC Markers in Breast Cancer 2020: What Have We Learned?
Open to view video.
Open to view video.
On Demand Webinar Survey
2 Questions
2 Questions Please complete the survey to receive your CEU certificate.
1.00 CEUs credit  |  Certificate available
1.00 CEUs credit  |  Certificate available